Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Filings indexed 1,611 across all filing types
Latest filing 2020-11-13 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年第3季財務報告書 — 202004_1734_AI3.pdf
Regulatory Filings
2020-11-13 Chinese
109年第3季財務報告書 — 202004_1734_AI1.pdf
Regulatory Filings
2020-11-13 Chinese
109年第3季財務報告書 — 202003_1734_AI1.pdf
Regulatory Filings
2020-11-13 Chinese
109年第3季財務報告書 — 202002_1734_AI1.pdf
Regulatory Filings
2020-11-13 Chinese
109年第3季財務報告書 — 202001_1734_AI1.pdf
Regulatory Filings
2020-11-13 Chinese
109年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning the company's investments in mainland China. It includes specific financial figures, investment methods, and notes explaining the data. The document length is 1500 characters, which is relatively short, but it contains substantive financial data rather than just an announcement or a link to a report. The content is regulatory in nature, providing investment disclosures likely required by a regulatory body, but it does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other financial reports. It is a regulatory disclosure about investments, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not neatly fit into other categories.
2020-11-13 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.